Insilico Medicine and Takeda entered a collaboration aimed at accelerating drug discovery. The arrangement assigns Insilico to AI-driven discovery and selection of molecules that meet predefined scientific and early development criteria, while Takeda applies its global development capabilities to advance selected candidates through validation steps.